证券代码：688177 证券简称：百奥泰 公告编号：2023-047 百奥泰生物制药股份有限公司 一、 前次募集资金基本情况 （一）前次募集资金的金额及到账情况 经上海证券交易所科创板上市委员会 2019 年 11 月 20 日审核同意，并经中 国证券监督管理委员会 2020 年 1 月 14 日《关于同意百奥泰生物制药股份有限公 司首次公开发行股票注册的批复》（证监许可[2020]92 号）注册同意，公司公开 发行人民币普通股 60,000,000 股，发行价格为人民币 32.76 元/股。募集资金总额 为人民币 1,965,600,000.00 元，募集资金净额为人民币 1,876,199,783.70 元。上述 募集资金已全部到位，并经由安永华明会计师事务所（特殊普通合伙）以安永华 明（2020）验字第 61494123_G03 号验资报告验证。 截止 2023 年 6 月 30 日 前次募集资金使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管 ...

关于归还暂时用于补充流动资金的闲置募集资金的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 百奥泰生物制药股份有限公司（以下简称"公司"）于 2022 年 8 月 23 日召 开第二届董事会第四次会议、第二届监事会第三次会议，审议通过了《关于使用 部分闲置募集资金暂时补充流动资金的议案》，同意公司在确保不影响募集资金 投资项目实施及募集资金使用的情况下，将不超过人民币 1 亿元暂时用于补充公 司流动资金。使用期限自董事会审议通过之日起不超过 12 个月。具体内容详见 公司于 2022 年 8 月 24 日在上海证券交易所网站（www.sse.com.cn）和指定媒体 刊登的《百奥泰关于使用部分闲置募集资金暂时补充流动资金的公告》（公告编 号：2022-042）。 证券代码：688177 证券简称：百奥泰 公告编号：2023-043 百奥泰生物制药股份有限公司 根据上述决议，公司在规定期限内使用了人民币 1 亿元闲置募集资金暂时补 充流动资金，并对资金进行了合理的安排与使用，没有影响募集资金投资项目建 设进度的正常 ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 证券代码：688177 证券简称：百奥泰 公告编号：2023-042 百奥泰生物制药股份有限公司 关于持股 5%以上股东减持股份计划公告 个自然日内减持股份总数不超过公司股本总数的 2%。减持期间如遇买卖股票的 窗口期限制，则停止减持股份。 一、减持主体的基本情况 | 股东名称 | 股东身份 | 持股数量 （股） | 持股比例 | 当前持股股份来源 | | | --- | --- | --- | --- | --- | --- | | 东台启恒（原吉 富启恒） | 5%以上非第 一大股东 | 21,499,471 | 5.19% | IPO前取得：21,499,471股 | | | 汇天泽 | 5%以下股东 | 4,560,931 | 1.10% | IPO 前取得：4,533,334 | 股 | | | | | | 其他方式取得：27,597 | 股 | | 合肥启兴 | 5%以下股东 | 2,776,804 | 0.67% | IPO 前取得： ...

证券代码：688177 证券简称：百奥泰 公告编号：2023-029 百奥泰生物制药股份有限公司 关于参加 2022 年度生物制品专场 集体业绩说明会的公告 百奥泰生物制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日在 上海证券交易所网站（www.sse.com.cn）披露《百奥泰 2022 年年度报告》。为加 强与投资者的深入交流，使投资者更加全面、深入地了解公司情况，公司参与了 由上海证券交易所主办的 2022 年度生物制品专场集体业绩说明会，此次活动将 采用视频和网络文字互动的方式举行，欢迎广大投资者积极参与。公司现就 2022 年度业绩说明会提前向广大投资者征集相关问题，广泛听取投资者的意见和建 议。 二、 说明会召开的时间、地点 本次说明会将于 2023 年 6 月 14 日（星期三）下午 14:00-15:00 在上海证券 会议召开时间：2023 年 6 月 14 日（星期三）下午 14:00-15:00 会议召开地点：上海证券交易所上证路演中心(http://roadshow.sseinfo.com) 会议召开方式：上证路演中心网络互动 交易所上证路演中心（http:// ...

Revenue and Profitability - Revenue for the first quarter of 2023 was RMB 154,927,728.15, representing a year-on-year increase of 108.74%[14] - Net profit attributable to shareholders of the listed company was RMB -142,584,813.68, with no applicable year-on-year comparison[14] - Total operating revenue for Q1 2023 was 154.93 million yuan, a significant increase from 74.22 million yuan in Q1 2022[54] - Revenue for Q1 2023 increased to 154,927,728.15 RMB, up from 74,220,560.73 RMB in Q1 2022, driven by increased sales of Geleri and Pubeixi, as well as new sales of Shireli[63][71] - Net loss for Q1 2023 was -142,584,813.68 RMB, compared to -110,363,404.74 RMB in Q1 2022, primarily due to increased R&D expenses[55][63] - Sales revenue from goods and services in Q1 2023 was 155,398,601.68 RMB, up from 132,161,441.42 RMB in Q1 2022[57][68] - Total comprehensive loss for Q1 2023 was -142,605,965.73 RMB, compared to -110,360,149.72 RMB in Q1 2022[56] - Net loss for the quarter was 143,294,729.60 RMB, compared to 110,355,571.09 RMB in the previous period[84] - Total comprehensive income loss was 143,294,729.60 RMB, compared to 110,355,571.09 RMB in the previous period[84] Shareholder Information - The largest shareholder, Guangzhou Qixi Group Co., Ltd., holds 159,690,670 unrestricted shares[9] - Therabio International Limited, a company wholly owned by LI SHENGFENG, holds 47,177,729 unrestricted shares[9] - Guangzhou Qiaoxing Investment Partnership holds 23,173,326 unrestricted shares[9] - Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership holds 21,499,471 unrestricted shares[9] - Guangzhou Zhongke Yuechuang No. 3 Venture Capital Partnership holds 21,333,332 unrestricted shares[9] - Guangzhou Xingyu Investment Partnership holds 21,320,002 unrestricted shares[9] Financial Position and Cash Flow - The company's monetary funds increased to 403,737,896.95 yuan as of March 31, 2023, compared to 165,938,818.90 yuan at the end of 2022[24] - Trade receivables rose to 125,758,587.34 yuan in Q1 2023, up from 89,753,379.06 yuan at the end of 2022[24] - Prepayments decreased to 49,616,974.60 yuan in Q1 2023 from 90,742,071.11 yuan at the end of 2022[24] - The company's cash flow from operating activities was -146,153,513.54 yuan in Q1 2023, compared to -56,794,194.40 yuan in the same period last year[32] - Cash flow from investing activities was 109,965,906.97 yuan in Q1 2023, a significant improvement from -162,230,429.04 yuan in the same period last year[32] - Cash flow from financing activities was 248,688,164.52 yuan in Q1 2023, compared to -30,913,695.25 yuan in the same period last year[32] - Operating cash flow was -146.15 million yuan, indicating a significant cash outflow[42] - Operating cash flow for Q1 2023 was -145,550,657.10 RMB, compared to -57,439,540.21 RMB in Q1 2022, reflecting higher cash outflows[68] - Investment cash flow for Q1 2023 was 110,022,326.97 RMB, a significant improvement from -162,113,314.04 RMB in Q1 2022, driven by higher returns on investments[68] - Monetary funds rose to 402,013,368.15 RMB, up 145.7% from 163,587,091.76 RMB[82] - Accounts receivable increased to 125,756,994.07 RMB, a 40.1% rise from 89,753,379.06 RMB[82] - Inventory grew to 194,091,534.90 RMB, up 19.9% from 161,899,105.30 RMB[82] Assets and Liabilities - The company's total assets increased to 2,333,289,046.26 yuan as of March 31, 2023, up from 2,181,047,560.11 yuan at the end of 2022[36] - Fixed assets decreased slightly to 525,504,178.82 yuan in Q1 2023 from 530,182,492.20 yuan at the end of 2022[36] - Construction in progress increased to 170,400,112.06 yuan in Q1 2023 from 155,832,688.66 yuan at the end of 2022[36] - The company's total liabilities increased to 582,317,299.21 yuan in Q1 2023 from 538,160,579.49 yuan at the end of 2022[36] - Total assets increased by 7.02% to 2.33 billion yuan compared to the previous year-end[42] - Shareholders' equity attributable to the parent company decreased by 8.87% to 1.46 billion yuan[42] - Contract liabilities increased to 331,975,545.60 RMB, up 8.8% from 305,080,691.59 RMB[73] - Total current liabilities rose to 582,653,895.81 RMB, an 8.2% increase from 538,503,100.22 RMB[73] - Long-term borrowings surged to 253,252,458.33 RMB, a significant jump from 3,002,458.33 RMB[73] - Total non-current liabilities increased to 285,358,116.58 RMB, up 739.7% from 33,978,620.55 RMB[73] - Total liabilities grew to 868,012,012.39 RMB, a 51.6% increase from 572,481,720.77 RMB[73] R&D and Operating Costs - Non-recurring gains and losses amounted to RMB 27,392,763.89, primarily driven by government subsidies of RMB 27,697,013.28[5][16] - Total R&D investment was 231.02 million yuan, accounting for 149.11% of revenue, a decrease of 42.15 percentage points[42] - Total operating costs for Q1 2023 were 323.39 million yuan, up from 198.03 million yuan in Q1 2022[54] - R&D expenses for Q1 2023 were 231.02 million yuan, compared to 141.96 million yuan in Q1 2022[54] - R&D expenses for Q1 2023 surged to 233,112,801.12 RMB, up from 143,317,997.75 RMB in Q1 2022, mainly due to increased clinical trial and technical service fees[63][71] - The company's R&D investment as a percentage of revenue decreased by 42.15 percentage points, as revenue growth outpaced R&D expense growth[71] Earnings and Share Performance - Basic and diluted earnings per share were both -0.34 yuan per share, reflecting a loss[42] - Weighted average return on equity was -9.28%, showing a decline in profitability[42] - Basic and diluted earnings per share for Q1 2023 were both -0.34 RMB, compared to -0.27 RMB in Q1 2022[56]

Product Development and Clinical Trials - The company has three products (Geleli®, Pubexi®, and Shiruili®) approved for sale in China, with one product (BAT2094) submitted for market approval and two products (BAT1706 and BAT1806) submitted to the FDA and EMA for approval[23]. - Five ADC products (BAT8006, BAT8007, BAT8008, BAT8009, and BAT8010) have entered clinical trials, showcasing the company's commitment to innovative cancer therapies[25]. - The company has received clinical trial approvals for multiple products throughout 2022, indicating ongoing development and regulatory engagement[29]. - The company has a significant number of products in various stages of clinical trials, with several in Phase I trials[31]. - The company has submitted applications for BAT2094 to NMPA and for BAT1706 and BAT1806 to FDA and EMA, indicating a strong pipeline of products nearing market entry[54]. - The company has multiple candidate drugs in late-stage clinical trials, including Gelerit® (Adalimumab), which has been approved for market in China[102]. - The product portfolio includes over 20 different products in clinical stages, focusing on tumor immunotherapy and antibody-drug conjugates (ADC) development[102]. - The company has developed a biosimilar drug, tocilizumab, which has been approved for marketing in China and is under review by the FDA and EMA[168]. Financial Performance and Investments - The company reported a research and development investment ratio of 135.43% of operating income, indicating a strong focus on R&D compared to industry peers[30]. - BTSBiopharma Inc. reported total assets of $1,828.78 million and net assets of $1,821.33 million, with a revenue of $8.70 million and a net profit of $0.45 million[37]. - The R&D investment for BAT2506 was $11,388.32 million, accounting for 25.02% of revenue, with a year-on-year increase of 54.29%[54]. - The R&D investment for BAT5906 was $3,608.60 million, representing 7.93% of revenue, with a year-on-year increase of 111.12%[54]. - The company reported a total revenue of 1.2 billion in 2022, representing a year-over-year growth of 15%[104]. - The company projects a revenue guidance of 1.5 billion for 2023, which reflects a growth target of 25%[106]. - New product launches are expected to contribute an additional 200 million in revenue in the next fiscal year[106]. - The company plans to not distribute profits or increase share capital from capital reserves for the 2022 fiscal year, pending shareholder approval[8]. Market Expansion and Strategic Initiatives - The company aims to develop innovative drugs and biosimilars for major diseases, focusing on PD-1 post-era tumor immunotherapy and ADC products[40]. - The company is actively pursuing global market expansion through strategic partnerships, with products like BAT2506 and BAT2206 currently in global Phase III clinical trials, aiming to address unmet clinical needs worldwide[65]. - Market expansion efforts include entering three new international markets, aiming for a 10% increase in market share by the end of the next fiscal year[80]. - The company has completed two strategic acquisitions in the last quarter, enhancing its market position[106]. - A new partnership with a leading tech firm is anticipated to drive innovation and product development[106]. Environmental and Social Responsibility - The company has implemented a rigorous environmental management system, ensuring compliance with local pollution discharge standards[89]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[85]. - The company has established a noise control plan to mitigate noise pollution from its operations[89]. - The company has made charitable contributions totaling 1,757.46 million yuan, including 29.50 million yuan in cash donations and 1,727.96 million yuan in donated medicines[169]. - The company actively participates in social responsibility initiatives, including a project to assist patients with autoimmune diseases[171]. - The company has committed to protecting consumer rights by establishing long-term partnerships with suppliers and adhering to strict quality assurance procedures[178]. Internal Management and Governance - The company has received a standard unqualified audit report from its accounting firm, ensuring the reliability of its financial statements[7]. - The internal control system is deemed adequate, ensuring the authenticity of financial reports and compliance with legal requirements[153]. - The company has established a system for managing insider information registration[113]. - The company has engaged in related party transactions, including signing supply contracts for construction projects[112]. - The company has established comprehensive management systems for energy consumption and pollutant emissions, including industrial wastewater, waste gas, noise, solid waste, and hazardous waste[124]. - The company has established a performance evaluation mechanism for senior management, which has been implemented during the reporting period[180]. - The company has implemented a comprehensive compensation policy that includes performance bonuses and various benefits[161]. Employee and Operational Metrics - The company reported a total of 1,189 employees, with 330 holding a college degree and 109 below that level[148]. - The employee composition includes 479 production personnel, 278 sales personnel, 352 technical personnel, 8 financial personnel, and 72 administrative personnel[159]. - The company organized annual training plans focusing on both business and management skills for its employees[148]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[152]. - User engagement metrics have improved, with a 30% increase in user retention rates compared to the previous year[80]. - The company reported a significant increase in user data, with a growth rate of 25% year-over-year in active users[80]. Compliance and Regulatory Matters - The company has received a warning letter from the China Securities Regulatory Commission regarding certain individuals, including the chairman and senior management[111]. - The company has successfully passed all resolutions in its shareholder meetings without any rejected proposals[91]. - The company did not adjust or change its cash dividend policy during the reporting period[149]. - The audit committee held 5 meetings during the reporting period, addressing various financial and operational proposals[142]. - The board of directors held 7 meetings during the year, all conducted via communication methods[155].

Financial Performance - The company's operating revenue for Q3 2022 was ¥152,791,176.23, representing a year-on-year increase of 76.17%[5] - The net profit attributable to shareholders for the same period was -¥86,491,752.30, with a year-to-date net profit of -¥255,621,854.06[5] - Total operating revenue for the first three quarters of 2022 was CNY 381,785,964.28, a decrease of 8.06% compared to CNY 415,396,572.73 in the same period of 2021[37] - The company reported a net loss of CNY 1,636,444,492.97 for the period, worsening from a loss of CNY 1,380,822,638.91 in the previous year[35] - The net profit for the third quarter was -255,621,854.06 RMB, compared to -111,824,394.81 RMB in the same period last year, indicating a significant increase in losses[42] - The total comprehensive income attributable to the parent company was -255,446,268.88 RMB, compared to -111,839,232.53 RMB in the previous year[45] - Basic and diluted earnings per share were both -0.62 RMB, compared to -0.27 RMB in the same quarter of the previous year[45] Research and Development - Research and development expenses totaled ¥155,665,540.09 in Q3 2022, accounting for 101.88% of operating revenue, a decrease of 65.03 percentage points compared to the previous year[8] - Research and development expenses for the first three quarters of 2022 were CNY 422,090,457.76, up from CNY 372,935,102.68, indicating a 13.2% increase year-over-year[41] - The company plans to continue focusing on R&D to drive future growth despite current financial challenges[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,349,889,374.33, down 10.23% from the end of the previous year[8] - Total assets decreased to CNY 2,349,889,374.33 from CNY 2,617,782,079.77, a decline of 10.24%[35] - Total liabilities decreased slightly to CNY 517,823,433.50 from CNY 530,269,870.06, a reduction of 2.6%[35] - Owner's equity decreased from CNY 2,089,178,501.28 to CNY 1,833,796,744.39, a decline of approximately 12.2%[64] Cash Flow - The cash flow from operating activities for the year-to-date was -¥266,574,644.11, indicating a decrease in cash inflow from licensing revenue compared to the previous year[8] - Cash flow from operating activities for the first nine months was -266,574,644.11 RMB, worsening from -132,701,105.63 RMB year-over-year[49] - Cash inflow from investment activities was 3,128,278,575.33 RMB, up from 2,558,185,810.50 RMB in the previous year[55] - Cash outflow from investment activities totaled 3,508,322,117.14 RMB, compared to 2,201,646,828.96 RMB in the same period last year[55] - The net cash flow from financing activities was -32,422,859.82 RMB, compared to 29,765,500.00 RMB in the previous year[55] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,234[16] - The top shareholder, Zhuhai Jifu Qiheng Medical Investment Partnership, holds 21,499,471 shares, representing a significant portion of the company's equity[22] - The company reported a total of 159,990,270 shares held by Guangzhou Qixi Group, indicating a strong control over the company[21] - The report indicates that the company has not issued any new shares during the quarter, maintaining the existing share structure[21] Future Outlook - The company plans to continue focusing on product sales and expanding its market presence in the upcoming quarters[15] - The company has not provided any specific guidance for future performance in the upcoming quarters[26] - There are no new product launches or technological advancements reported in this quarter[26] - The company has not announced any market expansion or acquisition strategies during this reporting period[26] - The financial report does not indicate any significant changes in the management or operational strategies[26] - The company has not highlighted any risks or challenges faced during the quarter that could impact future performance[26]

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a 20% increase compared to the same period last year[1]. - The company expects a revenue guidance of 1.2 billion RMB for the full year 2022, indicating a projected growth of 25%[3]. - The company reported a net profit margin of 15% for the first half of 2022, an increase from 12% in the previous year[10]. - The company's operating revenue for the first half of 2022 was ¥228,994,788.05, a decrease of 30.33% compared to ¥328,668,131.37 in the same period last year[30]. - The net profit attributable to shareholders of the listed company was -¥169,130,101.76, compared to a profit of ¥2,616,243.65 in the same period last year[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥187,988,358.79, compared to -¥15,058,116.35 in the same period last year[30]. - The net cash flow from operating activities was -¥118,318,082.51, compared to -¥186,039,940.82 in the same period last year[30]. - The net assets attributable to shareholders of the listed company at the end of the reporting period were ¥1,918,469,431.64, a decrease of 8.10% from ¥2,087,512,209.71 at the end of the previous year[30]. - The total assets at the end of the reporting period were ¥2,443,138,657.35, a decrease of 6.67% from ¥2,617,782,079.77 at the end of the previous year[30]. - The company's basic and diluted earnings per share for the reporting period were both -0.41 yuan, a decrease of 0.42 yuan per share compared to the same period last year[34]. User and Market Growth - User data indicates that the company has reached 1 million active users, a growth of 15% year-over-year[2]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[5]. - The company has completed the acquisition of a smaller biotech firm, which is expected to contribute an additional 100 million RMB in revenue annually[6]. - The company has established strategic partnerships with two major pharmaceutical companies to enhance distribution channels[9]. Research and Development - The company has invested 50 million RMB in R&D for new technologies aimed at enhancing product efficacy[7]. - Research and development expenses accounted for 116.35% of operating income, an increase of 46.93 percentage points year-on-year, indicating a significant rise in R&D investment[34]. - The company has established a comprehensive R&D platform and has accumulated extensive clinical trial experience, focusing on internal team-led drug development[73]. - The company is actively developing bispecific and multifunctional antibodies targeting tumors and autoimmune diseases, with candidates like BAT7104 and BAT2022 in early clinical research[87]. - The company has developed an advanced antibody library and IDEAL platform for antibody drug development, enhancing success rates for targeting new epitopes[83]. - The company has developed a proprietary culture medium technology that significantly reduces production costs and reliance on external suppliers[88]. Product Pipeline and Approvals - As of June 30, 2022, the company has two products approved for market in China, with additional products in various stages of clinical trials[56]. - The company has multiple products in clinical trials, including 3 in Phase III and 1 in Phase II, indicating a robust pipeline for future growth[59]. - The biosimilar drug Gralili (Adalimumab injection) received approval in November 2019 and has been approved for eight indications as of June 30, 2022, including five adult indications and three pediatric indications[62]. - The biosimilar drug Pubeshi (Bevacizumab injection) was approved in November 2021 and has five approved indications, including advanced non-small cell lung cancer and cervical cancer, as of June 30, 2022[63]. - The company has entered into commercialization agreements for Pubeshi with Cipla Gulf FZ LLC, Biomm SA, and Sandoz AG for various international markets[65]. Market and Industry Trends - The pharmaceutical manufacturing industry experienced a revenue decline of 0.6% year-on-year, with a profit drop of 27.6% in the same period[43]. - The rapid increase in new drug clinical trials in China reflects a heightened enthusiasm for drug development, with a notable increase of 29.1% in trial registrations compared to the previous year[44]. - The proportion of the population aged 65 and above in China reached 13.50% as of the latest census, indicating a growing demand for biopharmaceuticals due to aging-related diseases[53]. - The "14th Five-Year" plan emphasizes biopharmaceuticals as a key development area, aligning with the shift from "disease-centered" to "health-centered" approaches[53]. Risks and Challenges - The company has identified key risks including regulatory changes and market competition, which could impact future performance[8]. - The company faces risks related to significant market competition for its existing products and uncertainties regarding the commercialization of its pipeline products[145]. - The company is subject to regulatory risks that could affect its long-term operational performance due to changes in healthcare policies[158]. - The company faces significant risks related to supply chain stability for research and raw materials, which could impact profitability[152]. Environmental Compliance - The company has implemented strict pollution control measures, ensuring all pollutants are within the emission standards set by the environmental protection department[197]. - The wastewater treatment process includes hydrolysis acidification and contact oxidation, meeting the approved discharge requirements[198]. - The company has established an emergency response plan for environmental incidents, with no pollution accidents reported during the reporting period[199]. - The company has a self-monitoring scheme for environmental compliance, with all monitoring results meeting the approved discharge standards[200].

Financial Performance - The company's operating revenue for Q1 2022 was ¥74,220,560.73, representing a year-on-year increase of 23.08%[5] - The net profit attributable to shareholders was -¥110,363,404.74, with a net profit excluding non-recurring gains and losses of -¥122,886,437.18[5] - The net loss for Q1 2022 was CNY -110,363,404.74, slightly higher than the net loss of CNY -109,151,939.71 in Q1 2021[31] - The total comprehensive income attributable to the parent company was -110,360,149.72 RMB, slightly worse than -109,152,056.29 RMB in the previous year[33] - Basic and diluted earnings per share were both -0.27 RMB, compared to -0.26 RMB in Q1 2021[33] Cash Flow - The net cash flow from operating activities was -¥56,794,194.40[5] - The net cash flow from operating activities for Q1 2022 was CNY -57,439,540.21, an improvement compared to CNY -122,851,087.03 in Q1 2021, showing a reduction in cash outflow of 53.3%[55] - Cash received from sales of goods and services was 132,161,441.42 RMB, significantly up from 65,966,491.49 RMB in the same quarter last year[37] - Total operating cash inflows amounted to 149,250,669.45 RMB, compared to 82,782,177.81 RMB in Q1 2021[37] - The net cash flow from investment activities was -162,230,429.04 RMB, a decline from 56,104,913.68 RMB in Q1 2021[39] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,480,168,294.69, down 5.26% from the end of the previous year[8] - Total liabilities decreased from CNY 530,269,870.06 to CNY 503,016,234.70, representing a reduction of approximately 5.2%[25] - The company's total equity decreased from CNY 2,089,178,501.28 to CNY 1,978,822,930.19, a decline of 5.3%[48] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,673[12] - The largest shareholder, Guangzhou Qixi Group Co., Ltd., held 38.64% of the shares[12] - The top ten shareholders include entities such as Anhui Huizhi Fu Venture Capital Co., Ltd., holding 1,855,947 shares, which is approximately 4.4% of the total shares[14] Research and Development - Research and development expenses totaled ¥141,955,831.99, accounting for 191.26% of operating revenue, a decrease of 34.36 percentage points compared to the previous year[8] - Research and development expenses for Q1 2022 amounted to CNY 141,955,831.99, up from CNY 136,058,889.03 in Q1 2021, indicating a rise of approximately 4.4%[28] Market and Future Outlook - The company has not reported any new product launches or technological advancements during the quarter[17] - There are no significant market expansion or merger and acquisition activities disclosed in the current report[17] - The company has not provided specific future guidance or performance outlook for the upcoming quarters[17] Financial Statements - The financial statements for the quarter are unaudited, indicating that the figures may be subject to change upon final audit[19]

Financial Performance - The company reported no profit distribution or capital reserve transfer to share capital for the year 2021[7]. - The company has not achieved profitability since its listing[5]. - The company reported a significant increase in revenue, reaching approximately $150 million for the fiscal year, representing a 25% year-over-year growth[24]. - The company reported a net profit margin of 10%, up from 8% in the previous year[24]. - The total assets of the company increased to $500 million, reflecting a 12% growth compared to the previous year[24]. - The company's operating revenue for 2021 reached ¥836,578,620.84, a significant increase of 352.23% compared to ¥184,989,902.44 in 2020[35]. - The net profit attributable to shareholders was ¥81,936,544.64 in 2021, recovering from a loss of ¥513,226,538.86 in 2020[35]. - The net cash flow from operating activities improved to ¥236,270,932.55, up from a negative cash flow of ¥358,036,787.87 in the previous year[35]. - Basic earnings per share (EPS) for 2021 was ¥0.20, a turnaround from a loss of ¥1.27 per share in 2020[36]. - The company's total assets increased by 9.39% to ¥2,617,782,079.77 at the end of 2021, compared to ¥2,393,159,821.09 at the end of 2020[35]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥35,923,321.89, compared to a loss of ¥562,291,518.69 in 2020[35]. - The weighted average return on equity (ROE) improved to 4.00% in 2021, up from -26.35% in 2020[39]. Research and Development - The company is investing in R&D, allocating $20 million towards the development of new monoclonal antibodies[24]. - Research and development (R&D) expenses accounted for 64.96% of operating revenue, a decrease of 239.19 percentage points from the previous year[39]. - Total R&D investment for the year was approximately ¥543.42 million, a decrease of 3.42% compared to the previous year, with R&D expenses accounting for 64.96% of operating revenue[123]. - The company has developed a comprehensive antibody drug development technology covering antibody discovery, screening, design, process development, and validation[149]. - The company has established a leading antibody drug technology platform and is advancing multiple projects using the IDEAL engine[105]. - The company is developing bispecific and multifunctional antibodies targeting tumors and autoimmune diseases, with early clinical studies for BAT7104 targeting CD47 and PD-L1 already underway[116]. - The company has developed immunogenicity prediction technology to identify potential flaws in candidate molecules early in the development process, optimizing antibody structure and function[112]. Product Development and Pipeline - The company has 2 products approved for market launch and 23 major products under research, with 2 products having submitted market applications and 2 in Phase III clinical trials[55][66]. - The product Pubeixi® (Bevacizumab Injection) received approval in November 2021 for treating advanced, metastatic, or recurrent non-small cell lung cancer and metastatic colorectal cancer[55]. - The company’s biosimilar drug, BAT1806 (Tocilizumab injection), is currently under review by NMPA for indications including rheumatoid arthritis and cytokine release syndrome[76]. - BAT2506 (Guselkumab) is in global Phase III clinical trials and targets TNF-α, providing a new treatment option for patients with autoimmune diseases[77]. - The company has established collaborations for the commercialization of its products in emerging markets, including partnerships with Cipla and Sandoz[73]. - The company’s R&D pipeline includes multiple innovative drugs targeting various diseases, with several in late-stage clinical trials[70]. - The company has submitted applications for 2 products and has 2 products in Phase III clinical trials, 2 in Phase II, and 9 in Phase I clinical trials[148]. Market and Competitive Landscape - The global biopharmaceutical market is expected to grow from $204.8 billion in 2015 to $768 billion by 2030, with a compound annual growth rate (CAGR) of 9.4%[95]. - The Chinese biopharmaceutical market is projected to grow from RMB 145.3 billion in 2015 to RMB 1,302.9 billion by 2030, with a CAGR of 13.9%[95]. - The biopharmaceutical industry is highly competitive, with potential for rapid technological advancements that could impact existing products[164]. - The company faces risks related to the commercialization of its pipeline products, with potential market competition impacting profitability[160]. - The company is expanding into overseas markets, including the EU and the US, which may be affected by various geopolitical and economic factors[176]. Governance and Compliance - The audit report issued by Ernst & Young Huaming is a standard unqualified opinion[6]. - The company has not engaged in non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not violated decision-making procedures for external guarantees[11]. - The board of directors was fully present at the board meeting[6]. - The company has a risk statement regarding forward-looking statements in the report[8]. - The company has established governance structures to protect minority shareholders, but risks remain regarding potential undue influence from major shareholders[179]. Sales and Marketing - User data showed a 30% increase in active users, totaling 1.2 million by the end of the fiscal year[24]. - The company plans to enhance its digital marketing strategy, aiming for a 40% increase in online engagement[24]. - The marketing team has expanded the sales network across China, achieving steady revenue growth for the drug Gelerit® (Adalimumab Injection)[155]. - The company has established a sales team of over 240 people, covering all provinces, municipalities, and autonomous regions in China, excluding Hong Kong and Macau[87]. Risks and Challenges - The company acknowledges the high costs and complexities associated with drug development, which may affect the success of its projects[161]. - The company faces risks related to the loss of key technical personnel, which could delay the development of in-progress products[166]. - There is uncertainty regarding the commercialization of in-progress products, which may not achieve market acceptance or expected sales[168]. - Regulatory changes in the healthcare sector could impact the company's operations and financial performance, particularly regarding drug pricing and market access[175].